P2.12-08 Network Meta-Analysis of Angiogenesis Inhibitors on Survival of Patients with Small Cell Lung Cancer

This network meta-analysis aimed at providing a comprehensive evaluation of the effects of angiogenic inhibitors on small cell lung cancer by using network meta-analysis. The relative efficacy of angiogenesis inhibitors vandetanib (Van), bevacizumab (Bev), Rh-endostatin (End), sunitinib (Sun) and thalidomide (Tha) was evaluated by conducting a network meta-analysis of progression-free survival and overall survival. Nine phase II-III RCTs involving 1599 participants that investigated angiogenesis inhibitors on the treatment of SCLC were included. Sun and Bev achieved better PFS than Tha (Bev VS. Tha, HR=0.88, 95%CI: 0.79-0.98, Sun VS. Tha, HR=0.80, 95%CI: 0.65-1.00). Moreover, Sun and Bev were superior to placebo in terms of PFS (Bev VS. Placebo, HR=0.89, 95%CI: 0.81-0.97, Sun VS. Placebo, HR=0.81, 95% CI: 0.66-1.00). No significant difference of OS was found. In this network meta-analysis, the effect of sunitinib and bevacizumab may be superior to that of thalidomide for small cell lung cancer.